APR-246

DRUG9 trials

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia With Gene MutationsAcute Myeloid Leukemia or Myelodysplastic SyndromesChronic Myelomonocytic LeukemiaHematologic NeoplasmsHigh-grade Serous Ovarian CancerMelanomaMyelodysplastic Syndrome

Phase 1

Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer

CompletedNCT00900614

Aprea TherapeuticsHematologic Neoplasms, Prostatic Neoplasms

Start: 2009-05-31End: 2010-10-31Updated: 2019-07-31

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

CompletedNCT02098343

Aprea TherapeuticsPlatinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

Start: 2014-03-31End: 2019-04-30Updated: 2025-03-17

A Study of APR-246 in Oesophageal Cancer

TerminatedNCT02999893

Peter MacCallum Cancer Centre, AustraliaOesophageal Carcinoma

Start: 2017-04-11End: 2021-02-07Updated: 2021-12-13

Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms

CompletedNCT03072043

H. Lee Moffitt Cancer Center and Research InstituteAcute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome +1

Start: 2017-05-18End: 2021-12-08Updated: 2022-01-24

A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma

TerminatedNCT03391050

Aprea TherapeuticsMelanoma

Start: 2018-01-18End: 2018-08-08Updated: 2019-07-31

Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

NCT03588078

Groupe Francophone des MyelodysplasiesAcute Myeloid Leukemia With Gene Mutations, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Gene Mutation +1

Start: 2018-09-15End: 2021-05-15Updated: 2020-01-30

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

CompletedNCT04214860

Aprea TherapeuticsMyeloid Malignancy

Start: 2019-12-13End: 2022-01-14Updated: 2025-03-17

Phase 2

p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

CompletedNCT03268382

Aprea TherapeuticsHigh-grade Serous Ovarian Cancer

Start: 2017-07-31End: 2019-07-10Updated: 2025-03-17

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

CompletedNCT03931291

Aprea TherapeuticsAcute Myeloid Leukemia or Myelodysplastic Syndromes

Start: 2019-09-16End: 2022-01-14Updated: 2025-03-17

Frontiers in Immunology2026-07-03

The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications

Frontiers in Immunology2026-02-06

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML

HemaSphere2025-07-011 citations

Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.

2023-04-0153 citations

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies

Blood Advances2022-09-2355 citations

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine

Clinical Cancer Research2022-08-25136 citations

Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes

Journal of Clinical Oncology2022-07-11128 citations

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Blood2021-11-0541 citations

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes

Journal of Clinical Oncology2021-01-15432 citations

Phase 1 and Dose Expansion Study of APR-246 in Combination with Ibrutinib or Venetoclax-Based Therapy in Subjects with TP53-Mutant Relapsed and/or Refractory Non-Hodgkin Lymphomas (NHL) Including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

Blood2020-11-041 citations

Genetic markers and phosphoprotein forms of beta-catenin pβ-Cat552 and pβ-Cat675 are prognostic biomarkers of cervical cancer.

2020-10-209 citations

Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Blood2019-11-1373 citations

EUTROC PiSARRO: A phase Ib study combining APR-246 with standard chemotherapy in platinum sensitive relapsed high grade serous ovarian carcinoma (HGSOC).

Journal of Clinical Oncology2015-05-206 citations

APR-246

Sponsors

Conditions

Phase 1

Phase 2

Related Papers